Atreca, Inc.

Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations. The pipeline also includes APN-122597, a receptor tyrosine kinase engineered to specifically target tumor tissues, and ATRC-501/MAM01, an agent aimed at the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Beyond its internal programs, Atreca maintains strategic alliances, including a collaboration and licensing agreement with Xencor, Inc. for the research, development, and commercialization of innovative CD3 bispecific antibodies in oncology. Additionally, it holds a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the advancement and commercialization of MAM01/ATRC-501, specifically for malaria prevention. Founded in 2010, Atreca, Inc. is headquartered in San Carlos, California.